Floatz logo

Milvexian

Ischemic Stroke; Ischemic Attack, Transient

Janssen Research & Development, LLCSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Ischemic Stroke; Ischemic Attack, Transient cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Milvexian is also rated in:

transient ischemic attackDormant
B
Indicative ·
57 / 100
View asset →
ischemic strokeDormant
CCC
Indicative ·
51 / 100
View asset →
Healthy VolunteersDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →